Smar NetworkSmar.inSmargrid.comNewsInsuranceRoomsGamesMeasurements

Insurance Daily News

Daily news and analysis on insurance industry trends, regulations, and market insights

Facebook Telegram
← Back to Insurance News

GSK and Moderna Resolve Patent Dispute Over COVID and RSV Shots

📅 2026-11-10 | 📰 Insurance Journal
#gsk #moderna #patent settlement #covid-19 vaccine #rsv shot

British drugmaker GSK and U.S. biotech firm Moderna announced a settlement of patent litigation that covered Moderna’s COVID-19 vaccines Spikevax and mNEXSPIKE, as well as its RSV shot mResvia. The agreement, confirmed on October 28, includes cross-licensing of patents related to infectious-disease technologies, and neither party is required to make royalty payments under the licenses.

The settlement resolves GSK’s infringement claims filed in a Delaware federal court on October 6, which the companies asked to dismiss with prejudice, preventing any future refiling. GSK’s original lawsuit, filed in 2024, alleged that Moderna’s lipid-nanoparticle delivery system for messenger RNA infringed GSK patents. GSK has a separate, still-pending case against Pfizer and BioNTech over similar technology.

The resolution adds to a broader landscape of patent disputes among major vaccine makers, including a 2022 lawsuit filed by Moderna against Pfizer. The cross-license aims to provide clarity for both firms and allow continued focus on product innovation.

Why it matters

The settlement clarifies patent rights for key mRNA vaccine technologies, reducing legal uncertainty for insurers underwriting vaccine-related liabilities.

FAQ

What vaccines were involved in the GSK-Moderna settlement?
Moderna’s COVID-19 vaccines Spikevax and mNEXSPIKE, and its RSV shot mResvia.

Are any payments required under the new cross-licenses?
No, the companies are not obligated to make any payments in connection with the licenses.

What was the status of GSK’s lawsuit against Pfizer and BioNTech?
GSK’s lawsuit against Pfizer and BioNTech over their COVID-19 vaccine remains ongoing.

Source: Insurance Journal. See the original source for full details.